Mamoru Harada

4.4k citations

165 papers · 3.6k indexed · h-index 37

Immunology top 1%
- Immunotherapy and Immune Responses 91
- Immune Cell Function and Interaction 68
- T-cell and B-cell Immunology 45
- Immune cells in cancer 11
Oncology top 2%
- Cancer Immunotherapy and Biomarkers 38
- CAR-T cell therapy research 21
Hematology top 5%
Molecular Biology top 10%
- vaccines and immunoinformatics approaches 16
- RNA Interference and Gene Delivery 8
Cancer Research top 10%

Co-authors: Nanae Harashima Kyogo Itoh Masanori Noguchi Koji Tamada Kikuo Nomoto Satoko Matsueda Yuichi Iida Akira Yamada
Cited by: Immunology Oncology Hematology
Journals: Cancer Immunology Immunotherapy (15 papers)Cancer Science (12 papers)Oncology Reports (10 papers)
Partner nations: Japan United States Indonesia

In The Last Decade

Mamoru Harada

162 papers receiving 3.6k citations

Peers

Countries citing papers authored by Mamoru Harada

Since Specialization

Citations

This map shows the geographic impact of Mamoru Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mamoru Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mamoru Harada more than expected).

Fields of papers citing papers by Mamoru Harada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mamoru Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mamoru Harada. The network helps show where Mamoru Harada may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mamoru Harada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mamoru Harada Line = papers co-authored together Mamoru Harada links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103⁺ IL-12-producing dendritic cells and priming CD8⁺ T cells without involving draining lymph nodes Journal for ImmunoTherapy of Cancer ·Yuichi Iida,Mamoru Harada	2024	1
2	Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model Molecular Cancer Therapeutics ·Ryosuke Tanino,C.T. Walker,О. М. Головко,Rong Sun,Yukari Tsubata,Mamoru Harada,Yasuhisa Fujita,Takeshi Isobe	2019	86
3	Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells Oncology Reports ·Takanobu Motoshima,Yoshihiro Komohara,Hasita Horlad,Ario Takeuchi,Yoshihiro Maeda,Peter Voigt,Yoshiaki Kawano,Mamoru Harada,Motohiro Takeya,Masatoshi Eto	2015	19
4	The HSP70 and Autophagy Inhibitor Pifithrin-μ Enhances the Antitumor Effects of TRAIL on Human Pancreatic Cancer Molecular Cancer Therapeutics ·K. T. Muhammed Shafi,Nanae Harashima,Touko Inao,Shinji Okano,Yoshitsugu Tajima,Mamoru Harada	2013	38
5	Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells Cancer Immunology Immunotherapy ·Nanae Harashima,Bruno Jorge Duque da Silva,Ryu Imamura,Shinji Okano,Takashi Suda,Mamoru Harada	2011	58
6	Delayed growth of EL4 lymphoma in SR‐A‐deficient mice is due to upregulation of nitric oxide and interferon‐γ production by tumor‐associated macrophages Cancer Science ·Yoshihiro Komohara,Gabriela Sallum,Xiao Lei,Naomi Sakashita,Mamoru Harada,Hiroshi Suzuki,Tatsuhiko Kodama,Motohiro Takeya	2009	31
7	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients Oncology Reports ·E F ROBERTS,Yoshihiro Komohara,Shigeki Shichijo,Mamoru Harada,Ryuya Yamanaka,Shigeaki Miyamoto,Jun‐ichi Nikawa,Kyogo Itoh,Akira Yamada	2008	15
8	HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma Oncology Reports ·Yoshihiro Komohara,Mamoru Harada,Yuki Ishihara,Shigetaka Suekane,Masanori Noguchi,Akira Yamada,Kei Matsuoka,Kyogo Itoh	2007	22
9	Immunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients Cancer Science ·Yuji Sato,Toshiyoshi Fujiwara,Takashi Mine,Hiroki Shomura,Shigenori Homma,Yoshiaki Maeda,YaZhao,Yoshihiro Ikeda,Yuki Ishihara,Akira Yamada,Noriaki Tanaka,Kyogo Itoh,Mamoru Harada,Satoru Todo	2007	38
10	Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients Oncology Reports ·Yi Wang,Mamoru Harada,Hirohisa Yano,Sachiko Ogasawara,Masahiro Tanaka,Akira Yamada,Kyogo Itoh	2006	6
11	Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients Cellular Immunology ·Yi Wang,Yukari Takao,Mamoru Harada,Nobukazu Komatsu,Takeharu Ono,Michio Sata,Kyogo Itoh,Akira Yamada	2006	4
12	In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide The Journal of Immunology ·Mamoru Harada,Joe Liggio,Satoko Matsueda,Akira Muto,Tatsuya Oda,Yoshiko Iwamoto,Kyogo Itoh	2004	15
13	Identification of a prostate‐specific membrane antigen‐derived peptide capable of eliciting both cellular and humoral immune responses in HLA‐A24⁺ prostate cancer patients Cancer Science ·Kazuhiko Kobayashi,Masanori Noguchi,Kyogo Itoh,Mamoru Harada	2003	30
14	Elevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis Japanese Journal of Cancer Research ·Shigeru Yutani,Masatoshi Tanaka,Irwan Bastian. Skom. MMSi,E Picasso,Michio Sata,Shigeki Shichijo,Mamoru Harada,Kyogo Itoh	2002	2
15	Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes Leukemia ·Masanori Makita,Taichi Azuma,H Hamaguchi,Hironari Niiya,Keisuke Kojima,Shigeru Fujita,Mitsune Tanimoto,Mamoru Harada,Masaki Yasukawa	2002	37
16	Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients Japanese Journal of Cancer Research ·Koji Tanaka,Nanae Harashima,Fumihiko Niiya,Neemit Shah,Naoya Hida,M. P. Agusta,E Picasso,Mamoru Harada,Kyogo Itoh,Shigeki Shichijo	2002	6
17	Heat shock proteins and the antitumor T cell response Biotherapy ·Mamoru Harada,Genki Kimura,Mickaël Mestre	1998	22
18	Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes The Journal of Immunology ·Koji Tamada,Mamoru Harada,Koichiro Abe,Empirical Scintillation,Hitoshi Tada,Yidan Wu,K Nomoto	1997	61
19	Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production Cancer Immunology Immunotherapy ·Koichiro Abe,Mamoru Harada,Koji Tamada,Osamu Ito,Tieli Li,Kikuo Nomoto	1997	18
20	Use of a synthetic protease inhibitor for the treatment ofl-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation Annals of Hematology ·Masahiro Murakawa,Takashi Okamura,T Shibuya,Mamoru Harada,Takao Otsuka,Y Niho	1992	11

About Mamoru Harada

Mamoru Harada is a scholar working on Immunology, Oncology, Hematology, Molecular Biology and Cancer Research, having authored 165 papers that have together received 3.6k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (91 papers), Immune Cell Function and Interaction (68 papers), T-cell and B-cell Immunology (45 papers), Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (21 papers), vaccines and immunoinformatics approaches (16 papers), Immune cells in cancer (11 papers) and RNA Interference and Gene Delivery (8 papers). The work is most often cited by research in Immunology (2.0k citations), Oncology (1.4k citations), Hematology (320 citations), Molecular Biology (1.2k citations) and Cancer Research (235 citations). Mamoru Harada has collaborated with scholars based in Japan, United States and Indonesia. Frequent co-authors include Nanae Harashima, Kyogo Itoh, Masanori Noguchi, Koji Tamada, Kikuo Nomoto, Satoko Matsueda, Yuichi Iida, Akira Yamada, Ryosuke Tanino and Touko Inao. Their work appears in journals such as Cancer Immunology Immunotherapy, Cancer Science, Oncology Reports, International Journal of Oncology and Journal of Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact